Apogee Therapeutics (APGE) Assets Average (2023 - 2026)
Apogee Therapeutics (APGE) posted quarterly Assets Average of $1.1 billion for Q1 2026, up 51.95% year-over-year from $734.1 million in Q1 2025, and up 42.7% quarter-over-quarter from $781.6 million in Q4 2025.
Apogee Therapeutics (APGE) Assets Average (2023 - 2026) Analysis & Trends
Apogee Therapeutics (APGE) has reported Assets Average for 4 consecutive years, with $1.1 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 51.95% year-over-year to $1.1 billion; the TTM figure through Mar 2026 stood at $1.1 billion (up 51.95% YoY), while the FY2025 annual figure was $845.5 million, up 46.37% from the prior year.
- Assets Average advanced to $1.1 billion in Q1 2026 per APGE's latest filing, from $781.6 million in the prior quarter.
- Across five years, Assets Average topped out at $1.1 billion in Q1 2026 and bottomed at $278.5 million in Q3 2023.
- Historically, Assets Average has averaged $693.6 million across 4 years, with a median of $734.1 million in 2025.
- Annual changes were most pronounced in 2024 — Assets Average surged 183.07% — and 2025, when it decreased 18.58%.
- Apogee Therapeutics' Assets Average stood at $413.9 million in 2023, then jumped by 84.85% to $765.1 million in 2024, then rose by 2.16% to $781.6 million in 2025, then surged by 42.7% to $1.1 billion in 2026.
- Business Quant data shows APGE's Assets Average at $1.1 billion in Q1 2026, $781.6 million in Q4 2025, and $642.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Apogee Therapeutics | 10.14 Bn | 9.16 Bn | - | 1.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.31 Bn |
| Mar 31, 2026 | 1.12 Bn |
| Dec 31, 2025 | 781.65 Mn |
| Sep 30, 2025 | 641.97 Mn |
| Jun 30, 2025 | 685.97 Mn |
| Mar 31, 2025 | 734.06 Mn |
| Dec 31, 2024 | 765.12 Mn |
| Sep 30, 2024 | 788.47 Mn |
| Jun 30, 2024 | 812.16 Mn |
| Mar 31, 2024 | 612.53 Mn |
| Dec 31, 2023 | 413.91 Mn |
| Sep 30, 2023 | 278.54 Mn |